Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma.

Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma.
复制标题

CSF1R 阻断抗体对多发性骨髓瘤的治疗作用

DOI:
10.1038/leu.2017.193
复制
发表时间:
2018-01
期刊:
影响因子:
11.4
通讯作者:
Yi Q
Yi Q
中科院分区:
医学1区
文献类型:
--
作者:
Wang Q;Lu Y;Li R;Jiang Y;Zheng Y;Qian J;Bi E;Zheng C;Hou J;Wang S;Yi Q

文献摘要

参考文献

相似文献

我们之前的研究表明,巨噬细胞(MФs),尤其是骨髓瘤相关的MФs(MAMs)会在人类骨髓瘤中诱导化疗耐药。在这里,我们探索了通过使用集落刺激因子 1 受体 (CSF1R) 阻断单克隆抗体来靶向 MФ 来治疗骨髓瘤的潜力。我们的结果表明,CSF1R 阻断特异性抑制小鼠 M2 MФ 和 MAM 的分化、增殖和存活,并使 MAM 在体外重新极化为 M1 样 MФ。单独的 CSF1R 阻断可通过部分消耗 MAM、将 MAM 极化为 M1 表型并诱导肿瘤特异性细胞毒性 CD4+ T 细胞反应来抑制体内骨髓瘤生长。同样,在患有骨髓瘤的 MMDTR 小鼠中,基因耗尽 MФ 会延缓体内骨髓瘤的生长。此外,CSF1R 阻断与硼替佐米或美法仑等化疗的组合对已确诊的骨髓瘤显示出额外的治疗功效。最后,一种完全人源 CSF1R 阻断性单克隆抗体(与小鼠对应物类似)能够抑制人 MФ 的分化、增殖和存活。因此,这项研究提供了第一个直接的体内证据,证明 MΦ 和 MAM 确实对骨髓瘤的发生和进展很重要。我们的结果还表明,通过 CSF1R 阻断单克隆抗体靶向 MAM 可能是使骨髓瘤细胞(重新)对化疗敏感并促进患者抗骨髓瘤免疫反应的有前途的方法。
Our previous studies showed that macrophages (MФs), especially myeloma-associated MФs (MAMs) induce chemoresistance in human myeloma. Here we explored the potential of targeting MФs, by using colony-stimulating factor 1 receptor (CSF1R)-blocking mAbs, to treat myeloma. Our results showed that CSF1R blockade specifically inhibited the differentiation, proliferation and survival of murine M2 MФs and MAMs, and repolarized MAMs towards M1-like MФs in vitro. CSF1R blockade alone inhibited myeloma growth in vivo, by partially depleting MAMs, polarizing MAMs to the M1 phenotype, and inducing a tumor-specific cytotoxic CD4+ T cell response. Similarly, genetically depleting MФs in myeloma-bearing MMDTR mice retarded myeloma growth in vivo. Furthermore, the combination of CSF1R blockade and chemotherapy such as bortezomib or melphalan displayed an additive therapeutic efficacy against established myeloma. Finally, a fully human CSF1R blocking mAb, similar to its murine counterpart, was able to inhibit the differentiation, proliferation and survival of human MФs. Thus, this study provides the first direct in vivo evidence that MΦs and MAMs are indeed important for myeloma development and progression. Our results also suggest that targeting MAMs by CSF1R blocking mAbs may be promising methods to (re)sensitize myeloma cells to chemotherapy and promote anti-myeloma immune responses in patients.
DOI: 10.1371/journal.pone.0145342
发表时间: 2015
期刊: PloS one
影响因子: 3.7
作者:
Jablonski KA;Amici SA;Webb LM;Ruiz-Rosado Jde D;Popovich PG;Partida-Sanchez S;Guerau-de-Arellano M
通讯作者: Guerau-de-Arellano M
DOI: 10.1038/nri2528
发表时间: 2009-04
期刊: Nature reviews. Immunology
影响因子: --
作者:
通讯作者: --
DOI: 10.4049/jimmunol.177.10.7303
发表时间: 2006-11-15
影响因子: 4.4
作者:
Martinez, Fernando O.;Gordon, Siamon;Mantovani, Alberto
通讯作者: Mantovani, Alberto
DOI: 10.1158/0008-5472.can-04-0961
发表时间: 2004-08-01
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Aharinejad, S;Paulus, P;Abraham, D
通讯作者: Abraham, D
DOI: 10.1038/nm.3337
发表时间: 2013-10
期刊: Nature medicine
影响因子: 82.9
作者:
通讯作者: --